



We claim:

















1. Matrix metalloproteinase inhibitors having the general formula:




wherein r is 0-2, T is selected from the group consisting of:



and R<sup>40</sup> is selected from the group consisting of





and  $-\text{CH}_2\text{OCH}_2\text{OCH}_2\text{Ph}$ .

2. A composition having matrix metalloprotease inhibitory activity, comprising a compound  
5 of claim 1 and a pharmaceutically acceptable carrier.

3. A method of inhibiting matrix metalloprotease activity in a mammal comprising  
administration of an effective amount matrix metalloprotease inhibitor compound of claim 1 to said  
mammal.

4. The method of claim 3 wherein said mammal is a human.

10 5. A method of treating a mammal comprising administering to the mammal a matrix  
metalloprotease inhibiting amount of a compound according to claim 1 sufficient to:

(a) alleviate the effects of osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal  
disease, corneal ulceration, proteinuria, aneurysmal aortic disease, dystrophic  
epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated  
15 by MMP activity, temporomandibular joint disease, demyelinating diseases of the nervous  
system;

(b) retard tumor metastasis or degenerative cartilage loss following traumatic joint injury;

(c) reduce coronary thrombosis from atherosclerotic plaque rupture; or

(d) effect birth control.

20 6. The method of claim 5 wherein the effect is alleviation of osteoarthritis.

7. The method of claim 5 wherein the effect is retardation of tumor metastasis.